Merck touts updated 21-valent pneumococcal data weeks ahead of FDA decision
Merck bolstered its pneumococcal vaccine data on Monday, suggesting its experimental 21-valent shot V116 offers broader protection for older adults than Pfizer’s market-leading 20-valent Prevnar 20. An approval in the coming weeks would stoke Merck’s yearslong rivalry with Pfizer, whose Prevnar 20 was first approved in 2021, a mere month before